Company Filing History:
2 out of 730 
2 out of 272 
1 out of 314 
Years Active: 2004-2009
Title: Masabumi Shibuya: Innovator in Monoclonal Antibody Development
Introduction
Masabumi Shibuya is a prominent inventor based in Kawaguchi, Japan, known for his significant contributions to the field of medical science. With a portfolio of five patents, he is particularly recognized for his groundbreaking work on monoclonal antibodies that target the human VEGF receptor Flt-1, which plays a crucial role in various diseases characterized by abnormal angiogenesis.
Latest Patents
One of Masabumi Shibuya’s latest inventions is the anti-human VEGF receptor Flt-1 monoclonal antibody. This invention provides an antibody or peptide that immunologically reacts with the human VEGF receptor Flt-1, inhibiting the binding of human VEGF to this receptor. His work offers potential diagnostic and therapeutic means for treating diseases where abnormal angiogenesis is a factor, including the proliferation or metastasis of solid tumors, rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, and psoriasis.
Career Highlights
Throughout his career, Masabumi Shibuya has showcased remarkable inventiveness, primarily while working with notable companies such as Kyowa Hakko Kogyo Co., Ltd. and Kyowa Hakko Kirin Co., Limited. These establishments have provided platforms for his research and development in the field of biotechnology.
Collaborations
Masabumi Shibuya has collaborated with several esteemed professionals, including Kenya Shitara and Mikito Ito. Their collective expertise in scientific research has contributed to advancing the understanding and application of monoclonal antibodies.
Conclusion
In conclusion, Masabumi Shibuya stands out as a key figure in the innovation of monoclonal antibodies targeting the VEGF receptor. His work not only showcases his inventive spirit but also highlights the critical role that collaboration and industry partnerships play in advancing medical science. As diseases associated with abnormal angiogenesis continue to challenge healthcare, Shibuya's contributions remain pivotal in the ongoing quest for more effective treatments.